XOMA Stock Price, News & Analysis (NASDAQ:XOMA)

$31.59 -2.24 (-6.62 %)
(As of 12/15/2017 06:52 AM ET)
Previous Close$33.83
Today's Range$30.41 - $33.82
52-Week Range$3.96 - $34.44
Volume291,500 shs
Average Volume153,531 shs
Market Capitalization$275.51 million
P/E RatioN/A
Dividend YieldN/A
Beta3.19

About XOMA (NASDAQ:XOMA)

XOMA logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Debt-to-Equity Ratio3.53%
Current Ratio3.45%
Quick Ratio3.45%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.56 million
Price / Sales46.25
Cash FlowN/A
Price / CashN/A
Book Value($7.81) per share
Price / Book-4.04

Profitability

Trailing EPS($7.18)
Net Income$-53,530,000.00
Net Margins-3.51%
Return on Equity-1.14%
Return on Assets0.95%

Miscellaneous

Employees18
Outstanding Shares8,140,000

XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corporation (NASDAQ:XOMA) released its quarterly earnings data on Wednesday, November, 9th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($2.40) by $0.32. The biotechnology company earned $0.64 million during the quarter, compared to analysts' expectations of $1.29 million. XOMA had a negative net margin of 3.51% and a negative return on equity of 1.14%. XOMA's revenue for the quarter was down 69.1% on a year-over-year basis. View XOMA's Earnings History.

When will XOMA make its next earnings announcement?

XOMA is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for XOMA.

Where is XOMA's stock going? Where will XOMA's stock price be in 2017?

3 brokerages have issued 12 month price targets for XOMA's stock. Their predictions range from $19.00 to $38.00. On average, they anticipate XOMA's stock price to reach $28.50 in the next year. View Analyst Ratings for XOMA.

What are Wall Street analysts saying about XOMA stock?

Here are some recent quotes from research analysts about XOMA stock:

  • 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (11/10/2017)
  • 2. Cowen Inc analysts commented, "XOMA released additional data from its Phase II studies of XOMA 358 in patients." (2/1/2017)

Who are some of XOMA's key competitors?

Who owns XOMA stock?

XOMA's stock is owned by a number of of retail and institutional investors. Top institutional investors include EAM Investors LLC (0.52%) and OxFORD Asset Management LLP (0.33%). Company insiders that own XOMA stock include James R Neal, John Varian, Patrick J Md Phd Scannon, Paul D Rubin and Thomas M Burns. View Institutional Ownership Trends for XOMA.

Who bought XOMA stock? Who is buying XOMA stock?

XOMA's stock was acquired by a variety of institutional investors in the last quarter, including EAM Investors LLC and OxFORD Asset Management LLP. View Insider Buying and Selling for XOMA.

How do I buy XOMA stock?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $31.59.

How big of a company is XOMA?

XOMA has a market capitalization of $275.51 million and generates $5.56 million in revenue each year. The biotechnology company earns $-53,530,000.00 in net income (profit) each year or ($7.18) on an earnings per share basis. XOMA employs 18 workers across the globe.

How can I contact XOMA?

XOMA's mailing address is 2910 SEVENTH ST, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]


MarketBeat Community Rating for XOMA (XOMA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

XOMA (NASDAQ:XOMA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.402.402.14
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.50$28.50$17.00$8.67
Price Target Upside: 14.36% downside6.56% downside52.06% upside34.99% upside

XOMA (NASDAQ:XOMA) Consensus Price Target History

Price Target History for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2017HC WainwrightSet Price TargetBuy$38.00MediumView Rating Details
9/5/2017WedbushUpgradeNeutral -> Outperform$9.00 -> $19.00HighView Rating Details
2/1/2017CowenReiterated RatingHoldN/AView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
8/5/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
3/11/2016Royal Bank of CanadaReiterated RatingSector Perform$2.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

XOMA (NASDAQ:XOMA) Earnings History and Estimates Chart

Earnings by Quarter for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ XOMA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
3/16/2017Q4 2016($2.32)($2.89)$0.50 million$0.50 millionViewN/AView Earnings Details
11/9/2016Q3($2.40)($2.08)$1.29 million$0.64 millionViewN/AView Earnings Details
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)$1.17 million$3.96 millionViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

XOMA (NASDAQ:XOMA) Earnings Estimates

2017 EPS Consensus Estimate: ($2.50)
2018 EPS Consensus Estimate: ($1.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.65)($1.65)($1.65)
Q2 20171$0.38$0.38$0.38
Q3 20171($0.75)($0.75)($0.75)
Q4 20171($0.48)($0.48)($0.48)
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.51)($0.51)($0.51)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for XOMA (NASDAQ:XOMA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

XOMA (NASDAQ XOMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.02%
Institutional Ownership Percentage: 33.51%
Insider Trades by Quarter for XOMA (NASDAQ:XOMA)
Institutional Ownership by Quarter for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ XOMA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017James R. NealCEOSell46,296$28.24$1,307,399.04View SEC Filing  
11/15/2017Thomas M BurnsSVPSell22,222$28.69$637,549.18View SEC Filing  
11/13/2017James R. NealCEOSell11,568$30.83$356,641.44View SEC Filing  
11/13/2017Thomas M BurnsCFOSell6,983$30.99$216,403.17View SEC Filing  
5/16/2017John VarianDirectorSell39,540$6.24$246,729.60View SEC Filing  
3/21/2017James R. NealVPSell5,105$5.40$27,567.00View SEC Filing  
2/1/2017James R NealVPSell195$4.52$881.40View SEC Filing  
1/9/2017James R. NealVPSell125$5.15$643.75View SEC Filing  
12/21/2016John VarianDirectorSell13,549$5.75$77,906.75View SEC Filing  
12/21/2016Patrick J Md Phd ScannonVPSell3,230$5.75$18,572.50View SEC Filing  
11/1/2016James R. NealVPSell150$5.25$787.50View SEC Filing  
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.16View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.00View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.80View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.08View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.19View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.80View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.00View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.00View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.00View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.00View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.00View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.84View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.32View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.00View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.00View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.28View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.72View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.20View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

XOMA (NASDAQ XOMA) News Headlines

Source:
DateHeadline
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of ... - PR Newswire (press release)
www.prnewswire.com - December 12 at 4:41 PM
Form 8-K XOMA Corp For: Dec 06 - StreetInsider.comForm 8-K XOMA Corp For: Dec 06 - StreetInsider.com
www.streetinsider.com - December 12 at 4:41 PM
ETFs with exposure to XOMA Corp. : December 11, 2017ETFs with exposure to XOMA Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:35 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - December 11 at 11:12 AM
XOMA Corporation (XOMA) Expected to Announce Quarterly Sales of $1.61 MillionXOMA Corporation (XOMA) Expected to Announce Quarterly Sales of $1.61 Million
www.americanbankingnews.com - December 10 at 5:44 AM
 Brokerages Expect XOMA Corporation (XOMA) to Announce -$0.50 EPS Brokerages Expect XOMA Corporation (XOMA) to Announce -$0.50 EPS
www.americanbankingnews.com - December 8 at 7:46 PM
HC Wainwright Analysts Give XOMA (XOMA) a $38.00 Price TargetHC Wainwright Analysts Give XOMA (XOMA) a $38.00 Price Target
www.americanbankingnews.com - December 8 at 6:06 PM
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation ... - GlobeNewswire (press release)AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation ... - GlobeNewswire (press release)
globenewswire.com - December 8 at 10:36 AM
Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma CorporationToday’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation
finance.yahoo.com - December 8 at 10:36 AM
BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.
www.reuters.com - December 7 at 10:55 AM
XOMA (XOMA) Announces Exclusive Agreement Allowing Rezolute to Develop and Commercialize RZ358XOMA (XOMA) Announces Exclusive Agreement Allowing Rezolute to Develop and Commercialize RZ358
www.streetinsider.com - December 7 at 10:55 AM
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
finance.yahoo.com - December 7 at 10:55 AM
Head-To-Head Analysis: XOMA (XOMA) versus Soligenix (SNGX)Head-To-Head Analysis: XOMA (XOMA) versus Soligenix (SNGX)
www.americanbankingnews.com - December 6 at 1:46 AM
XOMA Corporation (XOMA) Given Consensus Rating of "Buy" by BrokeragesXOMA Corporation (XOMA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 4 at 5:08 AM
XOMA (XOMA) Upgraded to C- by TheStreetXOMA (XOMA) Upgraded to C- by TheStreet
www.americanbankingnews.com - December 1 at 10:34 PM
4 Biotech Stocks to Better Your Financial Health This Winter4 Biotech Stocks to Better Your Financial Health This Winter
www.zacks.com - December 1 at 5:47 PM
ETFs with exposure to XOMA Corp. : November 30, 2017ETFs with exposure to XOMA Corp. : November 30, 2017
finance.yahoo.com - November 30 at 4:24 PM
XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:38 AM
Head to Head Review: XOMA (XOMA) versus VBI Vaccines (VBIV)Head to Head Review: XOMA (XOMA) versus VBI Vaccines (VBIV)
www.americanbankingnews.com - November 27 at 5:28 AM
XOMA Corporation (XOMA) PT Set at $38.00 by HC WainwrightXOMA Corporation (XOMA) PT Set at $38.00 by HC Wainwright
www.americanbankingnews.com - November 25 at 1:32 PM
Reviewing Jazz Pharmaceuticals PLC (JAZZ) & XOMA Corporation (XOMA)Reviewing Jazz Pharmaceuticals PLC (JAZZ) & XOMA Corporation (XOMA)
www.americanbankingnews.com - November 25 at 1:24 AM
 Brokerages Expect XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million Brokerages Expect XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million
www.americanbankingnews.com - November 22 at 2:24 AM
 Analysts Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million Analysts Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million
www.americanbankingnews.com - November 19 at 10:36 AM
XOMA Corporation (XOMA) Expected to Post Earnings of -$0.50 Per ShareXOMA Corporation (XOMA) Expected to Post Earnings of -$0.50 Per Share
www.americanbankingnews.com - November 17 at 2:04 PM
XOMA Corporation (XOMA) CFO Thomas M. Burns Sells 6,983 SharesXOMA Corporation (XOMA) CFO Thomas M. Burns Sells 6,983 Shares
www.americanbankingnews.com - November 15 at 10:29 PM
Thomas M. Burns Sells 22,222 Shares of XOMA Corporation (XOMA) StockThomas M. Burns Sells 22,222 Shares of XOMA Corporation (XOMA) Stock
www.americanbankingnews.com - November 15 at 10:27 PM
XOMA Corporation (XOMA) CEO Sells $356,641.44 in StockXOMA Corporation (XOMA) CEO Sells $356,641.44 in Stock
www.americanbankingnews.com - November 15 at 10:27 PM
XOMA Corporation (XOMA) CEO Sells $1,307,399.04 in StockXOMA Corporation (XOMA) CEO Sells $1,307,399.04 in Stock
www.americanbankingnews.com - November 15 at 10:26 PM
The New Xoma - A Modified Risk Way Of Investing In The Genetic EraThe New Xoma - A Modified Risk Way Of Investing In The Genetic Era
seekingalpha.com - November 14 at 1:15 AM
XOMA Corporation (XOMA) Lifted to "Strong-Buy" at Zacks Investment ResearchXOMA Corporation (XOMA) Lifted to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - November 10 at 8:37 AM
XOMA Corporation (XOMA) Receives Average Recommendation of "Hold" from BrokeragesXOMA Corporation (XOMA) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 9 at 5:46 AM
XOMA Shines, PTGX Awaits Data, SELB Implodes, No Stopping NKTRXOMA Shines, PTGX Awaits Data, SELB Implodes, No Stopping NKTR
www.finanznachrichten.de - November 8 at 2:16 AM
45 Stocks Moving In Tuesdays Mid-Day Session45 Stocks Moving In Tuesday's Mid-Day Session
feeds.benzinga.com - November 7 at 12:58 PM
40 Stocks Moving In Tuesdays Pre-Market Session40 Stocks Moving In Tuesday's Pre-Market Session
feeds.benzinga.com - November 7 at 8:26 AM
XOMA Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)XOMA Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 1:25 AM
XOMA Reports Third Quarter 2017 Financial ResultsXOMA Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 8:24 PM
Xoma beats 3Q profit forecastsXoma beats 3Q profit forecasts
finance.yahoo.com - November 6 at 8:24 PM
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
finance.yahoo.com - November 6 at 9:42 AM
XOMA Corporation (XOMA) Rating Lowered to Hold at Zacks Investment ResearchXOMA Corporation (XOMA) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 2 at 9:10 AM
 Analysts Expect XOMA Corporation (XOMA) Will Announce Quarterly Sales of $17.95 Million Analysts Expect XOMA Corporation (XOMA) Will Announce Quarterly Sales of $17.95 Million
www.americanbankingnews.com - October 30 at 6:50 AM
XOMA Corporation (XOMA) Expected to Post Earnings of -$0.81 Per ShareXOMA Corporation (XOMA) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - October 28 at 9:06 AM
XOMA Corporation (XOMA) Stock Rating Upgraded by Zacks Investment ResearchXOMA Corporation (XOMA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 17 at 11:36 AM
HC Wainwright Initiates Coverage on XOMA Corporation (XOMA)HC Wainwright Initiates Coverage on XOMA Corporation (XOMA)
www.americanbankingnews.com - October 17 at 8:30 AM
XOMA Corporation (XOMA) Receives Average Rating of "Hold" from AnalystsXOMA Corporation (XOMA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 15 at 6:46 AM
XOMA Corporation (XOMA) Short Interest UpdateXOMA Corporation (XOMA) Short Interest Update
www.americanbankingnews.com - October 14 at 1:40 AM
Mateon Therapeutics (MATN) and XOMA Corporation (XOMA) Financial ContrastMateon Therapeutics (MATN) and XOMA Corporation (XOMA) Financial Contrast
www.americanbankingnews.com - October 13 at 10:28 PM
 Brokerages Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $770,000.00 Brokerages Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $770,000.00
www.americanbankingnews.com - October 11 at 1:52 PM
Critical Contrast: XOMA Corporation (XOMA) & Its RivalsCritical Contrast: XOMA Corporation (XOMA) & Its Rivals
www.americanbankingnews.com - October 6 at 4:28 AM
Financial Comparison: XOMA Corporation (XOMA) and Its PeersFinancial Comparison: XOMA Corporation (XOMA) and Its Peers
www.americanbankingnews.com - October 5 at 8:26 PM
XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries - GlobeNewswire (press release)XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries - GlobeNewswire (press release)
globenewswire.com - October 5 at 1:40 PM

SEC Filings

XOMA (NASDAQ:XOMA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

XOMA (NASDAQ:XOMA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

XOMA (NASDAQ XOMA) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.